To define its clinical relevance, we queried the TCGA database and found that high MTHFD2 mRNA is significantly correlated with poor prognosis in pancreatic, kidney, lung, breast, and liver cancer patients (Fig. 1f). This evidence concerns the gene MTHFD2 and liver cancer.